Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
2022, Heise, Mari et al
SGLT-2 inhibitors cause robust reduction of HHF and the renal outcome, and moderate reduction of CV or total deaths and MACE [13]
Lancet Diabetes Endocrinol 13(8):674684 Pv SG, Rada P, Valverde AM Cristina M
The effect of adding exenatide to thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial
FIGURE 1 QUESTION Based on the patients history and physical examination, which one of the following is the most likely diagnosis
US$ 29.70
US$ 23.31
US$ 28.28
US$ 26.44
US$ 27.76
US$ 27.68
